درباره این اپیزود
Eichenbaum Acorns is an editorially independent series powered by Modern Retina and hosted by David A. Eichenbaum, MD, FASRS, partner and director of research at Retina Vitreous Associates of Florida. This podcast series explores the overlooked corners of the retina profession through candid conversations with thought leaders. Eichenbaum is the Yiddish word for oak tree, and the aim of this series is to plant acorns of insight that grow into oaks of understanding.
In this episode, Eichenbaum speaks with two longtime friends and retina drug-development veterans: Andrea Gibson, PhD, executive vice president of medical collaborations at Ocular Therapeutix, and Erin C. Henry, PhD, AVP of Ophthalmology, General and Specialty Medicine, Value and Implementation, Global Medical and Scientific Affairs at Merck Research Labs.
Grab a seat for this one — it's part reunion, part masterclass. Gibson and Henry were there at the dawn of anti-VEGF therapy, trading stories from the front lines of a field that changed medicine forever, and 20 years later, they're still just as obsessed with the science. They swap laughs about "stumbling into" careers nobody could have mapped out for them, get real about the mentors who doubted the move to industry, and issue a challenge to the field: stop letting the next generation stumble in the same way they did. Equal parts nostalgia, candor, and a rallying cry for what comes next.
Check out more episodes of Eichenbaum Acorns, powered by Modern Retina, at https://www.ophthalmologytimes.com/podcasts/eichenbaum-acorns
رونوشت 🔗
جستجوی اپیزودهای گذشته
قسمت های دیگر در این پادکست
